Gilead Sciences stock rises around 3.5% as investors anticipate strong HIV and oncology earnings

Traders Union
All News
Stocks
Gilead Sciences surges 3.43% today

Highlights

Gilead Sciences expects third-quarter 2026 earnings per share of $2.18 to $2.19 and revenue of $7.80 to $7.81 billion, roughly flat year over year.
Recent performance shows continued strength in Biktarvy and growth in oncology from Trodelvy, with major acquisitions leading to significant related charges.
Shares of Gilead Sciences trade near session highs with bullish momentum, showing a likely short-term range of $161.16 to $167.01 and early signals of overbought conditions.

Earnings outlook steadies as HIV strengths offset acquisition costs

Gilead Sciences is set to report its third-quarter 2026 earnings on October 29, with expectations for earnings per share around $2.18 to $2.19 and revenue near $7.80–$7.81 billion, largely flat from a year earlier. Recent results showed ongoing strength in the HIV portfolio, especially Biktarvy, and growth in oncology from Trodelvy. Major acquisitions such as Arcellx, Tubulis, and Ouro Medicines recently closed, resulting in significant related charges. Gilead also secured a Canadian reimbursement agreement for LYVDELZI and continues strong cash generation, supporting dividends and share repurchases.

Anton Kharitonov, expert at Traders Union, notes Gilead's strong price action above several moving averages but flags caution. He observes mixed technical momentum and rising overbought signals, such as a high RSI and CCI. The flat revenue outlook and acquisition charges raise questions about near-term growth. Kharitonov sees the bullish gap as potentially unsustainable with volatility increasing. "Upside may be limited unless profit-taking reduces current overbought stress," he warns.

Viktoras Karapetjanc, expert at Traders Union, highlights Gilead's resilience amid steady top-line results and a robust HIV and oncology portfolio. He views new product reimbursements and recent acquisitions as catalytic for future growth. The bullish structure remains intact above $163.84, with technicals confirming market optimism. "Further growth is expected if Gilead sustains momentum and clears resistance at $167.01," he states.

Jainam Mehta, market strategist, sees current trading near session highs as a short-term strength signal. He notes divergence between positive MACD and cautious oscillators, suggesting price could consolidate or attempt a breakout above $167.01. "This divergence in momentum may create tactical setups for both breakout and mean-reversion trades," Mehta advises.

Bullish price structure holds as mixed signals warn of overbought risks

Gilead Sciences is trading above the 20-day, 50-day, and 200-day moving averages ($152.24, $149.95, and $139.43), reflecting persistent bullish momentum across short-, medium-, and long-term horizons. Immediate support and resistance are set by the near-term floor at $163.84 and ceiling at $167.01, with the longer-term bullish alignment remaining intact. Momentum signals are mixed: the MACD shows a buy reading, indicating positive momentum, but the ADX at 19.43 signals a neutral trend strength. RSI at 62.79 and CCI at 97.04 both tilt toward overbought territory, while the Stochastic RSI at 77.94 remains more neutral. Bull/Bear Power at 5.32 reveals intraday buyer dominance and warns of potential overbought conditions. The daily change is $5.46 higher, up 3.43%, after an upside gap of 1.83% ($2.91). The price is near the session high, with intraday volatility at 1.80%, showing strength toward the top of the range. However, oscillators and trend signals are diverging, with RSI and BBP suggesting possible exhaustion even as MACD stays positive.

Earlier, analysts noted that Gilead Sciences had established a bullish technical profile sustained by strong revenue growth and oncology pipeline developments. The current outlook builds on that foundation by highlighting persistent upward momentum and overbought signals, with $167.01 remaining a critical resistance level to monitor for a potential breakout.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.